ObsEva SA
BioSniper Score
4-factor signal
Market Cap
—
Cash Runway
2.0 mo
Lead Asset
nolasiban (Phase 3)
Next Catalyst
—
ObsEva SA: 1 pipeline candidate · 2 clinical trials · Updated within the last hour.
Go deeper on ObsEva SA with Spotter
Ask follow-up questions and run a full multi-agent deep dive on OBSA — live, with citations.
Score breakdown4-factor signal · derived from public data
2.0 months
D/E 0.95 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of December 31, 2022
Cash
$15.0M
Quarterly Burn
$23.1M
Revenue
$19.6M
Free Cash Flow
-$23.1M
Total Liabilities
$8.1M
Shareholders Equity
$8.5M
Current Ratio
2.23
Commercialization & Governance
Commercialization
- Status
- Late-stage clinical
- Has Revenue
- No
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| nolasiban | Phase 3 |
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on ObsEva SA
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.